A Phase I Trial of Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients
Latest Information Update: 13 Jun 2022
At a glance
- Drugs Obinutuzumab (Primary) ; Venetoclax (Primary)
- Indications Follicular lymphoma
- Focus Adverse reactions
- 09 Jun 2022 Status changed from active, no longer recruiting to completed.
- 24 Feb 2022 Planned End Date changed from 1 Dec 2021 to 1 Apr 2022.
- 24 Feb 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Apr 2022.